Melanosis and prolactin (bromocriptine)

• Autores: Coyotupa, Juan, Santa María, Carolina, Guitelman, Abraham
• Formato: artículo
• Fecha de Publicación: 2015
• Institución: Sociedad Peruana de Obstetricia y Ginecología
• Repositorio: Revista Peruana de Ginecología y Obstetricia
• Lenguaje: español
• OAI Identifier: oai:ojs.pkp.sfu.ca:article/1349
• Enlace del recurso: http://51.222.106.123/index.php/RPGO/article/view/1349
• Nivel de acceso: acceso abierto

This paper is a prospective evaluation of 59 patients with facial melanosis treatment they received as bromocriptine 5 mg / day for 6 months. After treatment of 51 patients improved and in 9 patients Melanosis melanosis persisted. In this study group 38 patients with hyperprolactinemia and after six months was found in 7 patients and 31 Hyperprolactinaemia persisted and were Normoprolactenemicas. Also in the group of 30 patients they had Galactorrea Melanosis and the end of treatment only 1 patient still had Galactorrea, while the remaining 37 were no longer Galactorrea. The fact that a dopamine fix on the one hand and on the other Melanosis hyperprolactinemia and galactorrhea, indicating that secretion of prolactin and alpha-MSH is under inhibitory control by dopamine would be the PIF and physiological MIF.